Compare Crispr Therapeutics AG (CRSP) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Microsoft — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Microsoft trades at $535.07 (market cap $3.88T). The key difference: Microsoft is far larger — about 795.1× Crispr Therapeutics AG's market cap, and Microsoft pays a 0.75% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Microsoft for 142 Days on average.
| CRSP | MSFT | |
|---|---|---|
Market Cap | $4.88B | $3.88T |
Volume | 2,861,747 | 19,593,392 |
Sector | Health | Technology |
52-Week High | $74.92 | $542.07 |
52-Week Low | $44.34 | $352.83 |
Typical Hold Time | 77 Days | 142 Days |
Enterprise Value | $3.30B | $3.86T |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
Microsoft (MSFT) trades at $522.61, down 1.35% on the day, with strong technical support at $517 and resistance at $530. The company demonstrates robust fundamentals with 2025 revenue of $281.72B and net income of $101.83B, maintaining a 40.31% net margin. Recent earnings beats and bullish analyst consensus support the stock's long-term growth trajectory despite near-term volatility.
Outlook remains positive with 81.7% analyst buy ratings and $571.76 consensus price target, representing 9.4% upside. Key risks include increased capital expenditure concerns and competitive pressures in AI, but Microsoft's strong cloud positioning and consistent earnings growth provide solid foundation for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
